{"denoms":[{"counts":[{"groupId":"BG000","value":"195"},{"groupId":"BG001","value":"207"},{"groupId":"BG002","value":"402"}],"units":"Participants"}],"groups":[{"description":"Participants received a fixed oral dose of 100 mg selinexor tablets (5 tablets of 20 mg each) QW on Days 1, 8, 15, 22, and 29 of each 35-day cycle, along with SC injection of 1.3 mg/m\\^2 bortezomib QW on Days 1, 8, 15, and 22 of each 35-day cycle, and an oral dose of 20 mg of dexamethasone BIW on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.","id":"BG000","title":"SVd Arm: Selinexor + Bortezomib + Dexamethasone"},{"description":"Participants received SC injection of 1.3 mg/m\\^2 bortezomib on Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles, followed by \\>= 9 cycles on Days 1, 8, 15, and 22 of each 35-day cycle, and received oral dose of 20 mg dexamethasone BIW on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles and for cycles \\>= 9 on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle until PD confirmed by the IRC, investigator or participant decision to discontinue study treatment, pregnancy, unacceptable AEs or toxicity that could not be managed by supportive care, withdrawal of consent, death, or sponsor decision to terminate the study.","id":"BG001","title":"Vd Arm: Bortezomib + Dexamethasone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.56","value":"65.3"},{"groupId":"BG001","spread":"9.35","value":"66.7"},{"groupId":"BG002","spread":"9.47","value":"66.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"172"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"230"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"50"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"11"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"161"},{"groupId":"BG001","value":"165"},{"groupId":"BG002","value":"326"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"14"}],"title":"Missing"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"171"},{"groupId":"BG001","value":"188"},{"groupId":"BG002","value":"359"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"25"}],"title":"Not Reported"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}],"title":"Unknown"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Missing"}],"title":"Ethnicity"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-treat (ITT) population consisted of all participants who were randomized to the study treatment, regardless of whether or not they received the study treatment."}